The estimated Net Worth of Cintia Piccina is at least $111 Mille dollars as of 18 June 2024. Cintia Piccina owns over 24,531 units of AlloVir stock worth over $29,103 and over the last 3 years Cintia sold ALVR stock worth over $82,289.
Sign up
Cintia Piccina ALVR stock SEC Form 4 insiders trading
Cintia has made over 3 trades of the AlloVir stock since 2022, according to the Form 4 filled with the SEC. Most recently Cintia sold 24,531 units of ALVR stock worth $22,814 on 18 June 2024.
The largest trade Cintia's ever made was selling 24,531 units of AlloVir stock on 18 June 2024 worth over $22,814. On average, Cintia trades about 9,577 units every 115 days since 2022. As of 18 June 2024 Cintia still owns at least 38,293 units of AlloVir stock.
You can see the complete history of Cintia Piccina stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cintia Piccina's mailing address?
Cintia's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Insiders trading at AlloVir
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... e Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
What does AlloVir do?
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
What does AlloVir's logo look like?
Complete history of Cintia Piccina stock trades at Adaptimmune Therapeutics Plc e AlloVir
AlloVir executives and stock owners
AlloVir executives and other stock owners filed with the SEC include:
-
David L. Hallal,
Exec. Chairman -
Vikas Sinha C.A., CPA, M.B.A.,
Pres, CFO & Director -
Vikas Sinha,
Pres, CFO & Director -
Dr. Ercem Atillasoy M.D.,
Chief Regulatory & Safety Officer -
Dr. Diana M. Brainard M.D.,
CEO & Director -
Sonia Choi,
Sr. VP of Corp. Affairs & Investor Relations -
Ugo Capolino Perlingieri,
Head & GM of Europe and Middle East Operations -
Dr. Jeroen Van Beek Ph.D.,
Chief Commercial Officer -
Edward Miller,
Gen. Counsel & Sec. -
Medha Chadha M.B.A.,
Sr. VP of Strategic Planning & Investor Relations -
Dr. Ann M. Leen Ph.D.,
Chief Scientific Officer -
Brett R. Hagen,
Chief Accounting Officer -
Agustin Melian M.D.,
Advisor -
Sciences, Inc. Gilead,
10% owner -
Edward Miller,
General Counsel -
Diana Brainard,
Chief Executive Officer -
Llc Elevate Bio,,
Director -
Juan Vera,
-
Group, Llc Green Jeremy Red...,
-
Ann M. Leen,
Chief Scientific Officer -
John Robert Wilson,
Director -
Ercem Atillasoy,
See Remarks -
Beek Jeroen B Van,
Chief Commercial Officer -
Agustin Melian,
Chief Medical Officer -
Brett R Hagen,
Chief Accounting Officer -
Ansbert Gadicke,
Director -
Morana Jovan Embiricos,
-
Vikas Sinha,
See Remarks -
Cintia Piccina,
Chief Commercial Officer -
Shawn Tomasello,
-
Malcolm Brenner,
-
David Hallal,
-
Jeffrey S Bornstein,